S. 3209

119 S3209 IS: Non-Opioids Prevent Addiction in the Nation for Veterans Act
 U.S. Senate
 2025-11-19
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 II  119th CONGRESS  1st Session  S. 3209  IN THE SENATE OF THE UNITED STATES   November 19, 2025   Mrs. Capito  (for herself,  Mrs. Shaheen ,  Mr. Cramer ,  Mr. King ,  Mr. Hoeven ,  Mrs. Gillibrand ,  Mr. Ricketts ,  Ms. Klobuchar ,  Mr. Justice ,  Mr. Kaine ,  Mrs. Britt ,  Mr. Van Hollen ,  Mr. Hagerty ,  Mr. Kelly ,  Mr. Scott of South Carolina ,  Ms. Cortez Masto , and  Ms. Rosen ) introduced the following bill; which was read twice and referred to the  Committee on Veterans' Affairs    A BILL
To amend title 38, United States Code, to ensure that the Secretary of Veterans Affairs furnishes certain non-opioid pain medications to veterans, and for other purposes.
1.
Short title
This Act may be cited as the   Non-Opioids Prevent Addiction in the Nation for Veterans Act   or the   NOPAIN for Veterans Act  .
2.
Inclusion of certain non-opioid pain medications in the National Formulary of the Department of Veterans Affairs
(a)
In general
Section 8125 of title 38, United States Code, is amended—
(1)
in subsection (d), by adding at the end the following new paragraph:
(4)
The term  non-opioid pain management drug or biological product  means a drug or biological product approved, granted, or cleared by the Food and Drug Administration to reduce postoperative pain, to produce postsurgical or regional analgesia, or to treat acute pain, without acting upon the body’s opioid receptors.
 ;
(2)
by redesignating subsection (d), as so amended, as subsection (e); and
(3)
by inserting after subsection (c) the following new subsection (d):
(d)
The Secretary shall include a non-opioid pain management drug or biological product in the national formulary of the Department not later than the earlier of—
(1)
one year after the date on which the non-opioid pain management drug or biological product becomes eligible for temporary additional payment under section 1833(t)(16)(G) of the Social Security Act ( 42 U.S.C. 1395l(t)(16)(G) ) or eligible for separate payment under section 416.174 of title 42, Code of Federal Regulations (or successor regulations); or
(2)
18 months after the date on which the non-opioid pain management drug or biological product is approved by the Food and Drug Administration.
 .
(b)
Limitation
None of the funds in the Cost of War Toxic Exposures Fund under section 324 of title 38, United States Code, may be used to carry out the amendments made by this section.
(c)
Implementation
Not later than 90 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall implement the amendments made by this section.